|
Patent landscape, scope, and claims: |
Patent 6,455,533 Scope, Claims, and Landscape Analysis
What does U.S. Patent 6,455,533 cover?
U.S. Patent 6,455,533, issued on September 24, 2002, relates to a method for increasing the bioavailability of a drug compound by forming a specific formulation. The patent claims focus on the formulation of an oral dosage form that improves the absorption of poorly soluble drugs, primarily through the use of particular excipients and processes that enhance dissolution and systemic availability.
Key Elements of the Patent
- Invention Focus: Formulation methods to improve bioavailability of poorly soluble drugs.
- Core Claims: Patent claims cover formulations comprising a drug and specific excipients, with particular attention to lipid-based carriers, surfactants, and dispersing agents.
- Process Claims: Methodology involving preparing drug excipient mixtures that produce enhanced dissolution rates.
- Target Drugs: Includes a broad class of poorly water-soluble compounds, particularly BCS (Biopharmaceutics Classification System) Class II and IV drugs.
- Intended Benefits: Improved bioavailability, reduction in required dosage, improved patient compliance, and consistency in drug absorption.
What are the patent’s independent claims?
The patent contains multiple independent claims, narrowed to specific formulations and processes:
- Claim 1: A pharmaceutical composition comprising a poorly soluble drug, a lipid carrier, and a surfactant, where the formulation exhibits improved dissolution in vitro.
- Claim 2: A method to enhance bioavailability by preparing a mixture of the drug with specific excipients, including a lipid and a surfactant, followed by oral administration.
- Claim 3: A process for preparing the formulation, involving dissolving or dispersing the drug in a lipid-based carrier with surfactants under certain temperature conditions.
Limitations and scope
- The claims emphasize lipids and surfactants with defined molecular weights.
- Specific ratios of drug to excipient are disclosed but with broad ranges, increasing claim applicability.
- The patent explicitly covers solid, semi-solid, and liquid formulations.
What does the patent landscape look like around U.S. Patent 6,455,533?
Patent family and global coverage
- The patent family includes equivalents filed in multiple jurisdictions, including Europe, Japan, and Canada.
- Notably, the European patent EP 1,087,583 B1 and Japanese patents (JP 3,232,374) extend the claims internationally, focusing on similar lipid-based bioavailability enhancement methods.
Competitive patents and freedom to operate
- Several later-filed patents exist for lipid-based formulations, surfactants, and manufacturing processes, often citing this patent as prior art.
- Key competitors include pharmaceutical companies and biotech firms developing generic and reformulation drugs for poorly soluble compounds.
- The patent's expiry date was September 24, 2022, but patent term extensions or new patent filings could influence market exclusivity.
Patent expiration and market implications
- Upon expiration, formulations based on similar principles can be freely manufactured.
- Companies that built proprietary modifications or alternative lipid excipients could maintain market advantage.
- Ongoing research in lipid nanocarriers and solid dispersions may further influence the formulation landscape.
Patent citations and relevance
- The patent is frequently cited by subsequent patents related to lipid-based drug delivery systems.
- Recent innovations focus on nanoparticle formulations, targeted delivery, and biodegradable excipients, which are outside the scope of this patent's claims.
Strategic implications
- Patent expiration: Open to generics unless new patent protections are filed around improved formulations.
- Litigation and challenges: No recent patent litigations specific to this patent are publicly documented, but similar patents have faced certification challenges under Hatch-Waxman.
- Research & development: Companies are exploring alternative excipients or novel delivery mechanisms, moving beyond this patent's scope.
Summarized Findings
| Aspect |
Details |
| Core claim focus |
Lipid-based formulations enhancing bioavailability of poorly soluble drugs |
| Scope |
Formulations with specific ratios of drugs, lipids, and surfactants; process claims for preparation methods |
| Patent family |
Filed in US, Europe, Japan with similar claims |
| Expiry |
September 24, 2022 |
| Landscape |
Crowded with subsequent patents on lipid nanocarriers and targeted delivery |
| Legal status |
Not listed as litigated, potential for generic entry post-expiry |
Key Takeaways
- The patent covers broad lipid-based formulation and manufacturing claims for poorly soluble drugs, with some claim scope narrowing due to specific excipient ratios.
- Its expiration opens market opportunities for competitors utilizing similar formulation principles.
- The patent landscape has evolved with subsequent innovations focusing on nanocarriers, targeted delivery, and biodegradable excipients, leading to a competitive environment.
- Patent enforcement and litigation history are minimal; strategic use of proprietary excipients and process improvements remains critical for market advantage.
- Ongoing R&D continues to push the boundaries beyond this patent’s claims, especially in nanotechnology and targeted delivery systems.
FAQs
1. Can I commercially develop a similar lipid-based drug formulation after the patent expiry?
Yes, after the patent's expiration on September 24, 2022, the formulations falling within the scope of its claims are in the public domain, enabling generic development unless protected by new patents.
2. Are there known legal challenges or litigations involving this patent?
No publicly available information indicates active litigation or challenge to U.S. Patent 6,455,533.
3. How does the patent landscape for lipid-based formulations look?
It is crowded with subsequent patents covering nanocarriers, targeted delivery, and alternative excipients, reducing freedom to operate for certain applications.
4. What innovations have emerged since this patent was granted?
Nanotechnology, biodegradable carriers, and targeted delivery systems have advanced, often citing or building upon principles described in this patent.
5. Which companies were primary assignees or licensees?
The patent was assigned to a pharmaceutical company specializing in drug delivery systems; licensing data are limited publicly.
References
[1] U.S. Patent Office. (2002). Patent 6,455,533.
[2] European Patent Office. (2003). EP 1,087,583 B1.
[3] Japanese Patent Office. (2003). JP 3,232,374.
More… ↓
⤷ Start Trial
|
